Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oramed Pharma (NQ: ORMP )

2.370 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oramed Pharma

< Previous 1 2 3 Next >
Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced top-line results from its Phase 3 trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26... 
Via Benzinga
Oramed Pharmaceuticals, Logitech International And Some Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Jim Cramer Says Avoid This Stock: 'Too Expensive'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Blackline, Inc. (NASDAQ: BL) was an enterprise software company that was losing money. 
Via Benzinga
Li Auto, XPeng, Nio And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Looking Into Oramed Pharmaceuticals's Return On Capital Employed
Via Benzinga
Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study
Via Benzinga
Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
Oramed Oral Insulin Shows Evidence For NASH Treatment
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced Phase 2 results from its trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes (T2D) patients with... 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
Oramed Pharmaceuticals (NASDAQ: ORMP) has enrolled over 50 percent of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the... 
Via Benzinga
Short Volatility Alert: Oramed Pharmaceuticals Inc.
On Wednesday, shares of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) experienced volatile short activity. After the activity, the stock price went up +4.16% to $8.77. The overall sentiment for ORMP has... 
Via Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Dow Rises 75 Points; Kura Sushi USA Shares Spike Higher
U.S. stocks traded slightly higher toward the end of trading as investors digested the recent jobs report for the month of June. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Tesla, Twitter And 76 Biggest Movers From Friday
Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022
Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) climbed 29.4% to close at $10.09. Synaptogenix... 
Via Benzinga
This Company Says Its Developing a COVID-19 Vaccine That Can be Taken Orally
Photo by FRANK MERIÑO from Pexels This post contains sponsored advertising content. This content is for informational purposes only and not intended to be... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adicet Bio (NASDAQ:ACET) stock increased by 37.85% to $13.51 during Monday's pre-market session. The market value of their outstanding shares is at $431.7... 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary Pasithea Clinics has been approved to provide... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 157.46% to $5.69 during Tuesday's pre-market session. The company's market cap stands at $75.1... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investors! We're getting right back to the grind today with a dive into the biggest pre-market stock movers for Tuesday. 
Via InvestorPlace
Exposures COVID-19 Product Safety
21 Stocks Moving In Tuesday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 201% to $4.00 in pre-market trading. The company filed proxy statement for annual meeting after the market close on... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of... 
Via Benzinga
40 Stocks Moving In Monday's Mid-Day Session
Gainers iSpecimen Inc. (NASDAQ: ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced research on COVID-19 seeking... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.